실적분석 2026년 8월 11일

Absci ($ABSI) Q2 2026 Earnings Analysis — Revenue Miss, Cash Runway Into H2 2028, Sharp After-Hours Drop

Earnings Scorecard

Revenue: $318K (-46.4% YoY, vs. $930K estimate) ❌ Miss

EPS (Earnings Per Share): Net loss of $0.21 per share (GAAP basic & diluted) · Estimate -$0.20 (adjusted basis) · Company did not disclose adjusted EPS, so the bases differ and are not directly comparable

Guidance: Newly provided — Cash and short-term investments are sufficient to fund operations into H2 2028 (No revenue or EPS quantitative guidance)

Stock Reaction: After-hours -15.83% ($7.92) — as of 08-12 06:07 Korean Standard Time

Positives

Cash Runway: $201.1M, sufficient to fund operations into H2 2028

Clinical Safety Profile: ABS-201 Phase 1 interim — tolerability favorable, half-life of 65+ days

Strategic Funding: $100M follow-on offering · $40M strategic investment from Eli Lilly

Absci is a clinical-stage biotech that designs antibodies using generative artificial intelligence. The message this quarter was less about near-term profit and loss and more about the upcoming androgenetic alopecia (pattern hair loss) and endometriosis candidate timelines along with the cash runway. The long half-life opens the possibility of dosing only 2-3 times every 6 months, which could serve as a key differentiator in dosing convenience.

Negatives

Revenue Miss: $318K came in well below the $930K estimate

Widening Losses: Net loss of $33.21M, larger than the prior-year period

Dilution from Equity Raise: June follow-on offering increased the float, weighing on per-share metrics

Partner program revenue declined year over year, highlighting the small-scale nature typical of clinical-stage companies. R&D expenses rose as internal pipeline candidates advanced through the clinic, and the loss-making structure is likely to persist until commercialization.

What Management Said

The CEO emphasized that positive interim results from the lead clinical program and a stronger financial structure position the company well for the next stage. Management framed the upcoming androgenetic alopecia proof-of-concept interim data in H2 of this year, the full 26-week results in early next year, and the endometriosis expansion as defining milestones ahead.

Market Reaction and What to Watch Next

Revenue came in well below expectations, and the clinical updates essentially repriced earlier disclosures, leaving limited new catalysts — that perception appears to have driven the after-hours selling pressure.

The content and market interpretation of ABS-201 androgenetic alopecia interim proof-of-concept data in H2 2026

Whether the endometriosis Phase 2 launch timeline in Q4 2026 is on track

Recovery in partner revenue, the quarterly cash-burn pace, and the need for additional financing